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all leaves was considered satisfactory. This condition was 
fulfilled by 36 of 44 participants. Follow-up of unsatisfactory 
results is on-going. 
 
Conclusions: The pilot audit of MLC performance has proven 
that the methodology for this audit worked well. About 80% 
of participants achieved satisfactory results. The hospitals 
with poor results were alerted of their MLCs sub-optimal 
performance. The positional accuracy of MLCs recorded in 
this audit is indicative of the accuracy relevant to clinical 
IMRT procedures. 
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Purpose/Objective: With regard to the complex dose 
distributions produced by active raster scanning, each 
treatment plan has to be verified before treatment. At the 
Heidelberg Ion-beam Therapy Center (HIT) patient specific 
dose verification is currently performed by using an array of 
24 ionization chambers. Due to the limited sampling period 
(~14 mm) of this system, a high resolution (~0.2 mm) flat 
panel detector has been investigated to supplement these 
dose measurements with fluence measurements in the dose 
plateau area of the depth dose distributions. 
Materials and Methods: A procedure is presented to correct 
the flat panel raw data and convert the corrected data into 
fluence distributions after suitable energy calibration. In the 
present work the fluence measurements have been realized 
using patient relevant accelerator settings. Additionally, a 
state of the art flat panel detector (XRD 0822 without 
scintillator, Perkin Elmer, Germany) was investigated with 
respect to signal quality and mandatory image corrections. 
After each measurement, the generated fluence distributions 
are checked against expected fluence distributions calculated 
from respective beam parameters. Using this method, 
fluence distributions can additionally be checked for each iso 
energy layer. To quantify the agreement between the 
measured and calculated fluence distributions a gamma index 
analysis has been performed. A global gamma index criterion 
of 5 % fluence deviation and 1 mm distance to agreement was 
used. Values below 3 % of the fluence maximum in each iso 
energy layer have not been taken into account.  
Results: Treatment plans with up to 2-3 Gy can be measured 
at the highest available beam intensity without any effects of 
detector signal saturation. So far, 6 proton treatment plans 
and 12 carbon ion treatment plans have been investigated. 
Averaged over all treatment plans, the gamma-index 
criterion was met in more than 98 % of the fluence values for 
protons and more than 96 % for carbon ions.  
Conclusions: A specific protocol was established to process 
flat panel raw data: It contains necessary offset, gain and 
bad pixel corrections, as well as an energy calibration. Based 
on two-dimensional high resolution fluence measurements in 
the dose plateau area of the depth dose distributions it is 
possible to provide supplementary information to 
conventional dose measurements. The corrected and 
calibrated flat panel detector signal shows promising results 
compared to the calculated data. However, before using this 
protocol in clinical routine, further studies, especially 
towards irradiation damage of the detector, have to be 
performed. So far, further bad pixels have not been 
detected.  
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Purpose/Objective: Flattening Filter Free (FFF) radiotherapy 
has recently become widely discussed in particular for 
stereotactic treatments where large doses per fraction (frac.) 
can be delivered quicker due to the higher dose rate. 
However, the original idea of FFF was not mainly to increased 
dose rate, but instead to reduce head scatter and thereby 
scattered dose to the entire patient. The purpose of this 
study was to investigate if normal fractionated treatments 
(1.8 – 2.0 Gy per frac.) could be delivered with clinically 
relevant dose accuracy and if there were any gains in 
treatment delivery because of the higher dose rate, or gains 
in treatment plans from the reduced scatter.  
Materials and Methods: In three of the main radiotherapy 
treatment sites (brain, head and neck (H&N) and lung) the 
first 10 curatively treated patients in 2014, having a single 
target and treated with a single full or half VMAT arc were 
selected. The patients were re-planned on Pinnacle ver. 9.8 
for the Elekta Versa HD linac. The dose prescriptions were 
59.4 Gy in 33 frac. for brain and 66 Gy in 33 frac. for H&N 
and lung. For each patient two plans were created with 
different beams (6 MV and 6 MV FFF). Both plans were 
optimised with the same fixed number of iterations and with 
no change to VMAT objectives. All treatment plans were 
delivered and dose accuracy evaluated using the Sun Nuclear 
ArcCheck phantom and analysed using a 3% and 3 mm global 
gamma between planned and measured doses. Beam on times 
were recorded for treatment beams. All DVH metrics were 
tested for significant differences with a paired two-sided 
Wilcoxon-signed rank test, with a significance level of 5%. 
Results: The mean dose to the body is reduced in the FFF 
treatment plans compared to the FF (Flattening Filter) plans 
for all 3 treatments sites (p=0.05, see table). For brain and 
H&N there are only small differences in target dose, however 
for the lung treatment PTV D2% (near max) and D98% (near 
minimum) the FFF plans are slightly less favourable. For H&N 
the FFF delivery is slower to deliver despite the higher dose 
rate. This might be due to the higher MLC modulation needed 
to compensate for the inhomogeneous profile of the FFF 
beam. The higher MLC modulation effect is seen for all three 
sites in the number of MU needed for the plans (p=0.002). 
The pass rate from the ArcCheck measurements are all 
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clinically acceptable, however the H&N FFF plans have lower 
pass rates. This can be related to the MLC modulation needed 
to compensate for the inhomogeneous beam profile using FFF 
for larger targets. Same trend is seen for the lung 
treatments, where there is a range of target sizes. 
 
 
Conclusions: Clinically acceptable FFF treatment plans can 
be created and delivered for normally fractionated 
treatments in all three anatomical sites. The reduced head 
scatter from removing the flattening filter produces reduced 
total body dose, which could be clinically relevant to the aim 
of reducing secondary cancers. 
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Purpose/Objective: Evaluation of the characteristics of the 
new EPID PV-aS1200 by Varian for its dosimetric usage with 
the GLAaS algorithm, where a dedicate configuration phase 
allows to convert the EPID reading into absorbed dose to 
water. 
Materials and Methods: The new PV-aS1200 imager has an 
active area of a 40x40cm2 (1190x1190 pixel), with a 
backscatter shielding included in the new cassette 
engineering. Its intrinsic characteristics were investigated on 
an Edge accelerator equipped with 6X, 6FFF, 10FFF beams. 
For the same energies, data were also compared to PV-
aS1000 acquisitions from a TrueBeam.  
A first level of investigations covered signal linearity with 
dose, response to primary and transmitted radiation, 
saturation relative to dose and dose rate, arm backscatter as 
a function of field size, ghosting. After that first detector 
assessment, the robustness of the GLAaS dose calibration 
process was evaluated in terms of absolute absorbed dose, 
relative output factors and profile parameters. 
Finally, GLAaS was validated for aS1200 as pre-treatment QA 
tool for RapidArc plans, covering different dose/fraction 
prescriptions. The mutual position of the detector and the 
linac head was measured in a cine mode during full rotations. 
Results: For all energies, aS1200 readings showed an optimal 
linearity relative to MU (R2=1.00), with a residual deviation 
less than 0.5% for more than 3MU. The detector response to 
primary and transmitted radiation was modelled and showed 
to be similar to the aS100 detector. The aS1200 confirmed to 
have no saturation for measurements at isocenter and the 
maximum dose rate (1400 and 2400 MU/min for 6 and 10FFF 
respectively). The arm backscatter variation with field size is 
now compensated with the new engineering. Consequently 
the dose calibration according to the GLAaS model was 
successfully implemented, allowing QA for all beams with no 
limitations of field size or dose rate.  
Comparison between measured dose map and TPS calculated 
dose in water was assessed through the Gamma Agreement 
Index GAI, for different DTA and ΔD criteria, resulting in GAI 
> 95% (2%, 2mm criteria).  
Conclusions: The new aS1200 detector improved the 
performance of the previous aS1000, with no more limitation 
in terms of field size and/or dose rate. The effective 
resolution of arm backscatter allows a more robust usage of 
the new detector. The usability for pre-treatment QA for 
RapidArc cases is confirmed in all conditions, from 
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Purpose/Objective: By creating Pareto fronts for Helical 
TomoTherapy (HT) plans, the influence of field width (FW), 
modulation factor (MF) and pitch on the plan quality can be 
investigated and Pareto optimal combinations can be 
deduced. 
Materials and Methods: For every oropharyngeal cancer 
patient out of five, 90 TomoEdge plans were made (each with 
a unique combination of MF and pitch) [1-2]. The 
homogeneity index (HI), conformity index (CI), Dnear-max (D2) 
and Dnear-min (D98) of the PTVs were plotted in a Pareto front 
